GENOFEN AS - 10101713 | Print Summary Report
STORYBOOK OÜ Tähe 129b, Tartu, 50113 ESTONIA (+372)7446645 info@scorestorybook.ee ssb.ee
[mo_oauth_login]

GENOFEN AS

Summary report

Date of report 25.03.2025

GENOFEN AS
10101713 - Registered
Founded in 01.10.1995
Fixed capital 25,565 €

VAT  
EE100242098 (start 01.10.1995)
start end
01.10.1995 -

Add GENOFEN AS data to your system

download JSON download CSV

Add GENOFEN AS data to your information system with one click or download a CSV file. The data is enriched with direct links to Storybook reports. See also the list of machine-readable data.

Don't have CRM? Read more

keywords

  • investeerimisfirmad
  • kinnisvara rentimine

GENOFEN AS

Scores and ratings

Reputation score

What is Reputation score?

Credit Score

Trustworthy 0.02

Loader
What is Credit Score?

Open the reports you want to print

Employees and salaries

GENOFEN AS

Number of employees and estimated average salaries
?

GENOFEN AS

Employee taxes and performance analysis
?
QuarterLabor taxes
paid		Number of employees
Turnover
Per Employee		Profit
per employee
2024 IV........................
2024 III........................
2024 II........................
2024 I........................
2023 IV........................
2023 III........................
2023 II........................
2023 I........................
2022 IV........................
2022 III........................
2022 II........................
2022 I........................
2021 IV........................
2021 III........................
2021 II........................
2021 I........................
2020 IV........................
2020 III........................
2020 II........................
2020 I........................
2019 IV........................
2019 III........................
2019 II........................
2019 I........................
2018 IV........................
2018 III........................
2018 II........................
2018 I........................
2017 IV........................
2017 III........................
2017 II........................
2017 I........................
2016 IV........................
2016 III........................
2016 II........................
2016 I........................
2015 IV........................
2015 III........................
2015 II........................
2015 I........................

Deciders and beneficiaries

GENOFEN AS

Decision-makers
?

Peter Lind

Relations: 2
Turnover 2024: 14 093 €
Employees: 3
Peter Lind
★★★★

......

Related companies scores

Credit Score: Neutral

Reputation score: 1210

Date of birth: ......

Active relations 2

Real Estate RentalPurchase and sale of own property
*Every member of the management board may represent the public limited company in concluding all transactions.

GENOFEN AS

History of right of representation
?
Field
Real Estate
Business age
29y
Beneficial country:
Estonia
 
Peter Lind ... - ...
1997
2001
2005
2009
2013
2017
2021
2025
1997
2000
2002
2005
2007
2010
2012
2015
2017
2020
2022
2025

GENOFEN AS

Owners
?

Former owners

NameCredit ScorePaymentBeginningTypeHolding
0.33
..................
100%

Former owners

NameCredit ScorePaymentBeginningEnding
0.33
..................
0.33
..................
!
..................

GENOFEN AS

Other related parties
?

Former other persons

NameCredit ScorePartBeginning
!
............
0.01
............
!
............
0.01
............
0.15
............

Other related parties (invalid relations)

NameCredit ScorePartBeginningEnding
0.01
..................
!
..................

GENOFEN AS

Subsidiaries and associates
?

Former subsidiaries and associates

NameCredit ScorePaymentBeginningTypeHolding
0.01
..................
50%
0.99
..................
2%

Former subsidiaries and associates

NameCredit ScorePaymentBeginningEnding
!
..................
0.01
..................
!
..................
0.99
..................
0.01
..................
0.01
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
0.01
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................
!
..................

Beneficiaries

Volumes and values ​​of beneficiaries' assets

Finances and assets

GENOFEN AS

Goodwill

GENOFEN AS

Taxes paid and estimated average salaries

GENOFEN AS

Quarterly indicators
QuarterTurnoverTaxed turnoverLabour productivityLabour productivityEmployeesNational taxesLabor taxes
2024 IV* ............* ..............................
2024 III* ............* ..............................
2024 II* ............* ..............................
2024 I* ............* ..............................
2023 IV* ............* ..............................
2023 III* ............* ..............................
2023 II* ............* ..............................
2023 I* ............* ..............................
2022 IV* ............* ..............................
2022 III* ............* ..............................
2022 II* ............* ..............................
2022 I* ............* ..............................
2021 IV* ............* ..............................
2021 III* ............* ..............................
2021 II* ............* ..............................
2021 I* ............* ..............................
2020 IV* ............* ..............................
2020 III* ............* ..............................
2020 II* ............* ..............................
2020 I* ............* ..............................
2019 IV* ............* ..............................
2019 III* ............* ..............................
2019 II* ............* ..............................
2019 I* ............* ..............................
2018 IV* ............* ..............................
2018 III* ............* ..............................
2018 II* ............* ..............................
2018 I* ............* ..............................
2017 IV* ............* ..............................
2017 III* ............* ..............................
2017 II* ............* ..............................
2017 I* ............* ..............................
2016 IV* ............* ..............................
2016 III* ............* ..............................
2016 II* ............* ..............................
2016 I* ............* ..............................
2015 IV* ............* ..............................
2015 III* ............* ..............................
2015 II* ............* ..............................
2015 I* ............* ..............................

GENOFEN AS

Sales revenue by business area

GENOFEN AS

Sales revenue by country

GENOFEN AS

Financial indicators and prognosis

GENOFEN AS

Financial raiting: "SATISFACTORY" (2024 prognosis)
2024 prognosis
LIQUIDITY
?
Net Working capital
...
Short-term debt coverage ratio
...
USE OF LOAN CAPITAL
?
Turnover ratio of fixed assets (X)
...
EFFECTIVENESS
?
Debt to assets ratio (X)
...
Capitalisation multiplier (X)
...
PROFITABILITY
?
Sales revenues (%)
...
Total asset revenues (%)
...
Equity revenues (%)
...
Unsatisfactory
1
2
3
4
5
Very good

GENOFEN AS

Real estate as of 25.03.2025

Active and unactive real estate

igon A......
igon T......
igon K......
igon T......
igon S......
igon K......
igon S......
igon P......
igon S......
igon M......

GENOFEN AS

Annual reports
Year Period Submitted Report PDF
2023 01.01.2023–31.12.2023 30.06.2024 ......
2022 01.01.2022–31.12.2022 27.06.2023 ......
2021 01.01.2021–31.12.2021 29.08.2022 ......
2020 01.01.2020–31.12.2020 17.06.2021 ......
2019 01.01.2019–31.12.2019 30.10.2020 ......
2018 01.01.2018–31.12.2018 24.07.2019 ......
2017 01.01.2017–31.12.2017 02.07.2018 ......
2016 01.01.2016–31.12.2016 13.06.2017 ......
2015 01.01.2015–31.12.2015 27.10.2016 ......
2014 01.01.2014–31.12.2014 03.07.2015 ......
2013 01.01.2013–31.12.2013 04.12.2014 ......
2012 01.01.2012–31.12.2012 28.06.2013 ......
2011 01.01.2011–31.12.2011 14.07.2012 ......
2010 01.01.2010–31.12.2010 06.07.2011 ......
2009 01.01.2009–31.12.2009 13.07.2010 ......
2008 01.01.2008–31.12.2008 01.07.2009 ......
2007 01.01.2007–31.12.2007 26.06.2008 ......
2006 01.01.2006–31.12.2006 23.07.2007 ......
2005 01.01.2005–31.12.2005 12.09.2006 ......
2004 01.01.2004–31.12.2004 19.09.2005 ......
2003 01.01.2003–31.12.2003 25.08.2004 ......
2002 01.01.2002–31.12.2002 01.07.2003 ......
2001 01.01.2001–31.12.2001 01.07.2002 ......
2000 01.01.2000–31.12.2000 02.07.2001 ......

Liabilities and debts

GENOFEN AS

Credit score history and prognosis
Recommended credit limit

... €

Recommended payment term

......

Business risk classes:

Trustworthy Neutral
Borderline Problematic Risky

GENOFEN AS

Reports and assets-liabilities overview 25.03.2025
?
Annual reports: ......
Annual reports: ......
Tax declarations:......
Assets to cover liabilities (short-term)
Assets: ...... €1 EURO of assets to cover short-term debt obligations: ...... €
Liabilities: ...... €Net Working capital: ...... €

GENOFEN AS

Claims history
?
1 month
6 months
Year
5 years
MAX
1 month
6 months
Year
5 years
MAX
Debt claims as of ......
Tax debt ...... €
Private debt ...... €

Total debt claims: ...... €

Latest events
...... ......

GENOFEN AS

Income (turnover) and expenditure (taxes paid)
?
QuarterTurnoverTaxed turnoverNational taxes paidLabor taxes paidNumber of employees
2024 IV* ...... €...... €...... €...... €......
2024 III* ...... €...... €...... €...... €......
2024 II* ...... €...... €...... €...... €......
2024 I* ...... €...... €...... €...... €......
2023 IV* ...... €...... €...... €...... €......
2023 III* ...... €...... €...... €...... €......
2023 II* ...... €...... €...... €...... €......
2023 I* ...... €...... €...... €...... €......
2022 IV* ...... €...... €...... €...... €......
2022 III* ...... €...... €...... €...... €......
2022 II* ...... €...... €...... €...... €......
2022 I* ...... €...... €...... €...... €......
2021 IV* ...... €...... €...... €...... €......
2021 III* ...... €...... €...... €...... €......
2021 II* ...... €...... €...... €...... €......
2021 I* ...... €...... €...... €...... €......
2020 IV* ...... €...... €...... €...... €......
2020 III* ...... €...... €...... €...... €......
2020 II* ...... €...... €...... €...... €......
2020 I* ...... €...... €...... €...... €......
2019 IV* ...... €...... €...... €...... €......
2019 III* ...... €...... €...... €...... €......
2019 II* ...... €...... €...... €...... €......
2019 I* ...... €...... €...... €...... €......
2018 IV* ...... €...... €...... €...... €......
2018 III* ...... €...... €...... €...... €......
2018 II* ...... €...... €...... €...... €......
2018 I* ...... €...... €...... €...... €......
2017 IV* ...... €...... €...... €...... €......
2017 III* ...... €...... €...... €...... €......
2017 II* ...... €...... €...... €...... €......
2017 I* ...... €...... €...... €...... €......
2016 IV* ...... €...... €...... €...... €......
2016 III* ...... €...... €...... €...... €......
2016 II* ...... €...... €...... €...... €......
2016 I* ...... €...... €...... €...... €......
2015 IV* ...... €...... €...... €...... €......
2015 III* ...... €...... €...... €...... €......
2015 II* ...... €...... €...... €...... €......
2015 I* ...... €...... €...... €...... €......

GENOFEN AS

Bailiff's enforcement proceedings as of 25.03.2025
?

Bailiff's enforcement proceedings MISSING

GENOFEN AS

Regulations of the Payment Order Department as of 25.03.2025
?

Regulations of the Payment Order Department MISSING

GENOFEN AS

Court orders in the register as of 25.03.2025
?

Court order MISSING

GENOFEN AS

Decisions of the Consumer Disputes Committee as of 25.03.2025
?

Consumer disputes MISSING

GENOFEN AS

Court hearings as of 25.03.2025
?

Court hearings MISSING

GENOFEN AS

Rulings as of 25.03.2025
?

Court settlemets MISSING

GENOFEN AS

Notices and announcements as of 25.03.2025
?

Announcements MISSING

Marketing

Business network

GENOFEN AS

 Business network
CREDIT RISK CLASSES
Deleted
Trustworthy
Neutral
Borderline
Problematic
Risky
Historical connection
Active connection
amount of turnover
amount of debt
Extension of networks
The network is visible with reduced links
Expand threads if desired

Beneficiaries network

GENOFEN AS

 Networks - Beneficiaries
The network is visible with reduced links
Expand threads if desired

Monitoring events

Filter

Dropdown

Year

Dropdown

Type

Neutral

Positive

Negative

No monitoring events found.

Failed to load monitoring events.

We value your privacy

We use cookies to improve your browsing experience, provide personalized ads or content, and analyze our traffic. By clicking "allow all", you agree to our use of all cookies.